Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis

European Journal of Immunology

Volumn 43, Issue 8, 2013, Pages 2194-2205

  Snyder Cappione, Jennifer E ^a   Nixon, Douglas F ^a   Chi, Joyce C ^a   Nguyen, Michelle Linh T ^a   Kirby, Christopher K ^a   Milush, Jeffrey M ^a   Koth, Laura L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Flow cytometry; Inflammation; Interferon gamma (IFN ); Invariant natural killer T (iNKT) cells; Sarcoidosis

Indexed keywords

C REACTIVE PROTEIN; CD56 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; MEMBRANE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INVARIANT NATURAL KILLER T CELL; LUNG FIBROSIS; LYMPHOCYTE COUNT; MALE; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOIDOSIS;

FLOW CYTOMETRY; INFLAMMATION; INTERFERON-GAMMA (IFN-Γ); INVARIANT NATURAL KILLER T (INKT) CELLS; SARCOIDOSIS;

ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, CD57; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; C-REACTIVE PROTEIN; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; INTERFERON-GAMMA; LECTINS, C-TYPE; LUNG DISEASES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; SARCOIDOSIS; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881533267     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201243185     Document Type: Article

References (62)

1. Bendelac, A., Lantz, O., Quimby, M. E., Yewdell, J. W., Bennink, J. R. and Brutkiewicz, R. R., CD1 recognition by mouse NK1+ T lymphocytes. Science 1995. 268: 863-865.
2. Bendelac, A., Rivera, M. N., Park, S. H. and Roark, J. H., Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 1997. 15: 535-562.
3. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H. et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997. 278: 1626-1629.
4. Tyznik, A. J., Tupin, E., Nagarajan, N. A., Her, M. J., Benedict, C. A. and Kronenberg, M., Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J. Immunol. 2008. 181: 4452-4456.
5. Nagarajan, N. A. and Kronenberg, M., Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 2007. 178: 2706-2713.
6. Subleski, J. J., Jiang, Q., Weiss, J. M. and Wiltrout, R. H., The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 2011. 3: 1167-1184.
7. Juno, J. A., Keynan, Y. and Fowke, K. R., Invariant NKT cells: regulation and function during viral infection. PLoS Pathog. 2012. 8: e1002838.
8. Reilly, E. C., Thompson, E. A., Aspeslagh, S., Wands, J. R., Elewaut, D. and Brossay, L., Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One 2012. 7: e37991.
9. Berzofsky, J. A. and Terabe, M., The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med. 2009. 9: 667-672.
10. Casorati, G., de Lalla, C. and Dellabona, P., Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. Oncoimmunology 2012. 1: 355-357.
11. Najera Chuc, A. E., Cervantes, L. A., Retiguin, F. P., Ojeda, J. V. and Maldonado, E. R., Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia. J. Cancer Res. Clin. Oncol. 2012. 138: 1427-1432.
12. Smyth, M. J., Thia, K. Y., Street, S. E., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T. et al., Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000. 191: 661-668.
13. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. and Brossay, L., Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 2012. 12: 239-252.
14. Wherry, E. J., T cell exhaustion. Nat. Immunol. 2011. 12: 492-499.
15. Fuller, M. J. and Zajac, A. J., Ablation of CD8 and CD4 T cell responses by high viral loads. J. Immunol. 2003. 170: 477-486.
16. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. and Ahmed, R., Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003. 77: 4911-4927.
17. Wherry, E. J. and Ahmed, R., Memory CD8 T-cell differentiation during viral infection. J. Virol. 2004. 78: 5535-5545.
18. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J. et al., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006. 439: 682-687.
19. Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H. et al., Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009. 458: 206-210.
20. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G. et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012. 366: 2455-2465.
21. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D. et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012. 366: 2443-2454.
22. Moll, M., Kuylenstierna, C., Gonzalez, V. D., Andersson, S. K., Bosnjak, L., Sonnerborg, A., Quigley, M. F. et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur. J. Immunol. 2009. 39: 902-911.
23. Kee, S. J., Kwon, Y. S., Park, Y. W., Cho, Y. N., Lee, S. J., Kim, T. J., Lee, S. S. et al., Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. Infect. Immun. 2012. 80: 2100-2108.
24. Song, Z., Marzilli, L., Greenlee, B. M., Chen, E. S., Silver, R. F., Askin, F. B., Teirstein, A. S. et al., Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J. Exp. Med. 2005. 201: 755-767.
25. Chen, E. S. and Moller, D. R., Sarcoidosis-scientific progress and clinical challenges. Nat. Rev. Rheumatol. 2011. 7: 457-467.
26. Iannuzzi, M. C., Rybicki, B. A. and Teirstein, A. S., Sarcoidosis. N. Engl. J. Med. 2007. 357: 2153-2165.
27. Ho, L. P., Urban, B. C., Thickett, D. R., Davies, R. J. and McMichael, A. J., Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005. 365: 1062-1072.
28. Kobayashi, S., Kaneko, Y., Seino, K., Yamada, Y., Motohashi, S., Koike, J., Sugaya, K. et al., Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis. Int. Immunol. 2004. 16: 215-222.
29. Kirtland, S. H. and Winterbauer, R. H., Pulmonary sarcoidosis. Semin. Respir. Med. 1993. 14: 344-352.
30. Lee, P. T., Benlagha, K., Teyton, L. and Bendelac, A., Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 2002. 195: 637-641.
31. Gumperz, J. E., Miyake, S., Yamamura, T. and Brenner, M. B., Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002. 195: 625-636.
32. Berzins, S. P., Cochrane, A. D., Pellicci, D. G., Smyth, M. J. and Godfrey, D. I., Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur. J. Immunol. 2005. 35: 1399-1407.
33. - subsets of Valpha24-invariant natural killer T cells in humans. Blood 2004. 104: 4150-4156.
34. Snyder-Cappione, J. E., Loo, C. P., Carvalho, K. I., Kuylenstierna, C., Deeks, S. G., Hecht, F. M., Rosenberg, M. G. et al., Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 2009. 23: 1965-1970.
35. Terasaki, F., Ukimura, A., Tsukada, B., Fujita, S., Katashima, T., Otsuka, K., Kanzaki, Y. et al., Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ. J. 2008. 72: 1303-1307.
36. Antoniou, K. M., Tzouvelekis, A., Alexandrakis, M. G., Tsiligianni, I., Tzanakis, N., Sfiridaki, K., Rachiotis, G. et al., Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J. Interferon Cytokine Res. 2006. 26: 400-405.
37. Day, C. L., Abrahams, D. A., Lerumo, L., Janse van Rensburg, E., Stone, L., O'Rie, T., Pienaar, B. et al., Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 2011. 187: 2222-2232.
38. Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M., Altman, J. D. and Ahmed, R., Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998. 188: 2205-2213.
39. Lucas, M., Gadola, S., Meier, U., Young, N. T., Harcourt, G., Karadimitris, A., Coumi, N. et al., Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol. 2003. 77: 2251-2257.
40. Azakami, K., Sato, T., Araya, N., Utsunomiya, A., Kubota, R., Suzuki, K., Hasegawa, D. et al., Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009. 114: 3208-3215.
41. Sandberg, J. K., Fast, N. M., Palacios, E. H., Fennelly, G., Dobroszycki, J., Palumbo, P., Wiznia, A. et al., Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 2002. 76: 7528-7534.
42. Snyder-Cappione, J. E., Nixon, D. F., Loo, C. P., Chapman, J. M., Meiklejohn, D. A., Melo, F. F., Costa, P. R. et al., Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J. Infect. Dis. 2007. 195: 1361-1364.
43. Tahir, S. M., Cheng, O., Shaulov, A., Koezuka, Y., Bubley, G. J., Wilson, S. B., Balk, S. P. et al., Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 2001. 167: 4046-4050.
44. van der Vliet, H. J., von Blomberg, B. M., Hazenberg, M. D., Nishi, N., Otto, S. A., van Benthem, B. H., Prins, M. et al., Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J. Immunol. 2002. 168: 1490-1495.
45. Focosi, D., Bestagno, M., Burrone, O. and Petrini, M., CD57+ T lymphocytes and functional immune deficiency. J. Leukoc. Biol. 2010. 87: 107-116.
46. Bendelac, A., Savage, P. B. and Teyton, L., The biology of NKT cells. Annu. Rev. Immunol. 2007. 25: 297-336.
47. Matsuda, J. L., Mallevaey, T., Scott-Browne, J. and Gapin, L., CD1d-restricted iNKT cells, the "Swiss-Army knife" of the immune system. Curr. Opin. Immunol. 2008. 20: 358-368.
48. De Santo, C., Salio, M., Masri, S. H., Lee, L. Y., Dong, T., Speak, A. O., Porubsky, S. et al., Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 2008. 118: 4036-4048.
49. De Santo, C., Arscott, R., Booth, S., Karydis, I., Jones, M., Asher, R., Salio, M. et al., Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat. Immunol. 2010. 11: 1039-1046.
50. Kim, C. H., Johnston, B. and Butcher, E. C., Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002. 100: 11-16.
51. Snyder-Cappione, J. E., Tincati, C., Eccles-James, I. G., Cappione, A. J., Ndhlovu, L. C., Koth, L. L. and Nixon, D. F., A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-alpha and MIP1-beta, a lack of IL-17, and a Th1-bias in males. PLoS One 2010. 5: e15412.
52. Parekh, V. V., Lalani, S., Kim, S., Halder, R., Azuma, M., Yagita, H., Kumar, V. et al., PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 2009. 182: 2816-2826.
53. Chang, W. S., Kim, J. Y., Kim, Y. J., Kim, Y. S., Lee, J. M., Azuma, M., Yagita, H. et al., Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 2008. 181: 6707-6710.
54. Sullivan, B. A. and Kronenberg, M., Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J. Clin. Invest. 2005. 115: 2328-2329.
55. Costabel, U. and Hunninghake, G. W., ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 1999. 14: 735-737.
56. Hunninghake, G. W., Costabel, U., Ando, M., Baughman, R., Cordier, J. F., du Bois, R., Eklund, A. et al., ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc. Diffuse Lung Dis. 1999. 16: 149-173.
57. Watters, L. C., King, T. E., Schwarz, M. I., Waldron, J. A., Stanford, R. E. and Cherniack, R. M., A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1986. 133: 97-103.
58. James, D. G. and Thomson, A. D., The course of sarcoidosis and its modification by treatment. Lancet 1959. 1: 1057-1061.
59. Scadding, J. G., Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br. Med. J. 1961. 2: 1165-1172.
60. Roederer, M., Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 2001. 45: 194-205.
61. Sandberg, J. K., Bhardwaj, N. and Nixon, D. F., Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 2003. 33: 588-596.
62. Lee, P. T., Putnam, A., Benlagha, K., Teyton, L., Gottlieb, P. A. and Bendelac, A., Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 2002. 110: 793-800.